Prognostic values of ALDOB expression and 18F-FDG PET/CT in hepatocellular carcinoma

PurposeThe glycolytic enzyme fructose 1,6-bisphosphate aldolase B (ALDOB) is aberrantly expressed and impacts the prognosis in hepatocellular carcinoma (HCC). Hepatic ALDOB loss leads to paradoxical upregulation of glucose metabolism, favoring hepatocellular carcinogenesis. Nevertheless, the relatio...

Full description

Bibliographic Details
Main Authors: Wenzhi Jia, Qianyun Wu, Xiaofeng Yu, Mengqin Shen, Ruixue Zhang, Jiajin Li, Li Zhao, Gang Huang, Jianjun Liu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1044902/full
_version_ 1828084655946989568
author Wenzhi Jia
Qianyun Wu
Xiaofeng Yu
Mengqin Shen
Ruixue Zhang
Jiajin Li
Li Zhao
Gang Huang
Jianjun Liu
author_facet Wenzhi Jia
Qianyun Wu
Xiaofeng Yu
Mengqin Shen
Ruixue Zhang
Jiajin Li
Li Zhao
Gang Huang
Jianjun Liu
author_sort Wenzhi Jia
collection DOAJ
description PurposeThe glycolytic enzyme fructose 1,6-bisphosphate aldolase B (ALDOB) is aberrantly expressed and impacts the prognosis in hepatocellular carcinoma (HCC). Hepatic ALDOB loss leads to paradoxical upregulation of glucose metabolism, favoring hepatocellular carcinogenesis. Nevertheless, the relationship between ALDOB expression and 18F-fluorodeoxyglucose (18F-FDG) uptake, and their effects on HCC prognosis remain unclear. We evaluated whether ALDOB expression is associated with 18F-FDG uptake and their impacts on HCC prognosis prediction.MethodsChanges in ALDOB expression levels and the prognostic values in HCC were analyzed using data from The Cancer Genome Atlas (TCGA) database. Ultimately, 34 patients with HCC who underwent 18F-FDG positron emission tomography/computed tomography (PET/CT) preoperatively were enrolled in this retrospective study. ALDOB expression was determined using immunohistochemistry (IHC) staining, and the maximum standardized uptake value (SUVmax) of HCC was calculated from the 18F-FDG PET/CT scans. The relationship between ALDOB expression and SUVmax was examined, and their impacts on overall survival were evaluated using Cox proportional hazards models and Kaplan–Meier survival analysis. ALDOB overexpression in HUH7 and 7721 cells was used to analyze its role in tumor metabolism.ResultsAccording to TCGA database, the ALDOB mRNA level was downregulated in HCC compared to normal tissue, and significantly shortened overall survival in HCC patients. ALDOB protein expression was similarly decreased in IHC findings in HCC than that in adjacent normal tissues (P<0.05) and was significantly associated with tumor size (P<0.001), high tumor-node-metastasis stage (P=0.022), and elevated SUVmax (P=0.009). ALDOB expression in HCC was inversely correlated with SUVmax (r=-0.454; P=0.012), and the optimal SUVmax cutoff value for predicting its expression was 4.15. Prognostically, low ALDOB expression or SUVmax ≥3.9 indicated shorter overall survival time in HCC. Moreover, COX regression analysis suggested high SUVmax as an independent prognostic risk factor for HCC (P=0.036). HCC patients with negative ALDOB expression and positive SUVmax (≥3.9) were correlated with worse prognosis. ALDOB overexpression in HCC cells significantly decreases 18F-FDG uptake and lactate production.ConclusionSUVmax in HCC patients is inversely correlated with ALDOB expression, and 18F-FDG PET/CT may be useful for ALDOB status prediction. The combined use of ALDOB expression and 18F-FDG PET/CT data can provide additional information on disease prognosis in HCC patients.
first_indexed 2024-04-11T04:29:17Z
format Article
id doaj.art-5b3fff0aa89d45638984b176657204cf
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-04-11T04:29:17Z
publishDate 2022-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-5b3fff0aa89d45638984b176657204cf2022-12-29T11:19:07ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.10449021044902Prognostic values of ALDOB expression and 18F-FDG PET/CT in hepatocellular carcinomaWenzhi JiaQianyun WuXiaofeng YuMengqin ShenRuixue ZhangJiajin LiLi ZhaoGang HuangJianjun LiuPurposeThe glycolytic enzyme fructose 1,6-bisphosphate aldolase B (ALDOB) is aberrantly expressed and impacts the prognosis in hepatocellular carcinoma (HCC). Hepatic ALDOB loss leads to paradoxical upregulation of glucose metabolism, favoring hepatocellular carcinogenesis. Nevertheless, the relationship between ALDOB expression and 18F-fluorodeoxyglucose (18F-FDG) uptake, and their effects on HCC prognosis remain unclear. We evaluated whether ALDOB expression is associated with 18F-FDG uptake and their impacts on HCC prognosis prediction.MethodsChanges in ALDOB expression levels and the prognostic values in HCC were analyzed using data from The Cancer Genome Atlas (TCGA) database. Ultimately, 34 patients with HCC who underwent 18F-FDG positron emission tomography/computed tomography (PET/CT) preoperatively were enrolled in this retrospective study. ALDOB expression was determined using immunohistochemistry (IHC) staining, and the maximum standardized uptake value (SUVmax) of HCC was calculated from the 18F-FDG PET/CT scans. The relationship between ALDOB expression and SUVmax was examined, and their impacts on overall survival were evaluated using Cox proportional hazards models and Kaplan–Meier survival analysis. ALDOB overexpression in HUH7 and 7721 cells was used to analyze its role in tumor metabolism.ResultsAccording to TCGA database, the ALDOB mRNA level was downregulated in HCC compared to normal tissue, and significantly shortened overall survival in HCC patients. ALDOB protein expression was similarly decreased in IHC findings in HCC than that in adjacent normal tissues (P<0.05) and was significantly associated with tumor size (P<0.001), high tumor-node-metastasis stage (P=0.022), and elevated SUVmax (P=0.009). ALDOB expression in HCC was inversely correlated with SUVmax (r=-0.454; P=0.012), and the optimal SUVmax cutoff value for predicting its expression was 4.15. Prognostically, low ALDOB expression or SUVmax ≥3.9 indicated shorter overall survival time in HCC. Moreover, COX regression analysis suggested high SUVmax as an independent prognostic risk factor for HCC (P=0.036). HCC patients with negative ALDOB expression and positive SUVmax (≥3.9) were correlated with worse prognosis. ALDOB overexpression in HCC cells significantly decreases 18F-FDG uptake and lactate production.ConclusionSUVmax in HCC patients is inversely correlated with ALDOB expression, and 18F-FDG PET/CT may be useful for ALDOB status prediction. The combined use of ALDOB expression and 18F-FDG PET/CT data can provide additional information on disease prognosis in HCC patients.https://www.frontiersin.org/articles/10.3389/fonc.2022.1044902/fullhepatocellular carcinomatumor progressionprognosis18F-FDG PET/CTALDOB
spellingShingle Wenzhi Jia
Qianyun Wu
Xiaofeng Yu
Mengqin Shen
Ruixue Zhang
Jiajin Li
Li Zhao
Gang Huang
Jianjun Liu
Prognostic values of ALDOB expression and 18F-FDG PET/CT in hepatocellular carcinoma
Frontiers in Oncology
hepatocellular carcinoma
tumor progression
prognosis
18F-FDG PET/CT
ALDOB
title Prognostic values of ALDOB expression and 18F-FDG PET/CT in hepatocellular carcinoma
title_full Prognostic values of ALDOB expression and 18F-FDG PET/CT in hepatocellular carcinoma
title_fullStr Prognostic values of ALDOB expression and 18F-FDG PET/CT in hepatocellular carcinoma
title_full_unstemmed Prognostic values of ALDOB expression and 18F-FDG PET/CT in hepatocellular carcinoma
title_short Prognostic values of ALDOB expression and 18F-FDG PET/CT in hepatocellular carcinoma
title_sort prognostic values of aldob expression and 18f fdg pet ct in hepatocellular carcinoma
topic hepatocellular carcinoma
tumor progression
prognosis
18F-FDG PET/CT
ALDOB
url https://www.frontiersin.org/articles/10.3389/fonc.2022.1044902/full
work_keys_str_mv AT wenzhijia prognosticvaluesofaldobexpressionand18ffdgpetctinhepatocellularcarcinoma
AT qianyunwu prognosticvaluesofaldobexpressionand18ffdgpetctinhepatocellularcarcinoma
AT xiaofengyu prognosticvaluesofaldobexpressionand18ffdgpetctinhepatocellularcarcinoma
AT mengqinshen prognosticvaluesofaldobexpressionand18ffdgpetctinhepatocellularcarcinoma
AT ruixuezhang prognosticvaluesofaldobexpressionand18ffdgpetctinhepatocellularcarcinoma
AT jiajinli prognosticvaluesofaldobexpressionand18ffdgpetctinhepatocellularcarcinoma
AT lizhao prognosticvaluesofaldobexpressionand18ffdgpetctinhepatocellularcarcinoma
AT ganghuang prognosticvaluesofaldobexpressionand18ffdgpetctinhepatocellularcarcinoma
AT jianjunliu prognosticvaluesofaldobexpressionand18ffdgpetctinhepatocellularcarcinoma